Impact of a ketogenic diet on metabolic and psychiatric health in patients with schizophrenia or bipolar illness*

To initiate a low-carbohydrate, high-fat ketogenic dietary intervention among a small cohort of outpatients with either schizophrenia or bipolar illness and comorbid overweight/obesity currently taking psychotropic medications.

​

Stanford-affiliated

FDA Approved Medication to Reduce Binge Eating and/or Purging*

This study will demonstrate the efficacy of Qsymia versus placebo in treating bulimia nervosa and binge eating disorder.

​

Stanford-affiliated

Ketogenic diet for psychotic disorders

This randomised, controlled pilot study aims to investigate the feasibility of a Modified Ketogenic Diet intervention protocol in psychotic inpatients, and the potential impact of this intervention on psychotic symptoms, depressive and anxiety symptoms, and functioning in patients with psychotic symptoms / psychotic disorder.

​

Externally-conducted